These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28972704)

  • 1. Successful Treatment of Major Depressive Disorder With Add-On Buprenorphine in a Patient With Previous Nonresponse to Standard Antidepressants.
    Elsayed M; Gahr M; Connemann BJ; Schönfeldt-Lecuona C
    Prim Care Companion CNS Disord; 2017 Sep; 19(5):. PubMed ID: 28972704
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder.
    Ragguett RM; Rong C; Rosenblat JD; Ho RC; McIntyre RS
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):475-482. PubMed ID: 29621905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of buprenorphine in the treatment of drug-resistant depression - an overview of the studies.
    Stefanowski B; Antosik-Wójcińska A; Święcicki Ł
    Psychiatr Pol; 2020 Apr; 54(2):199-207. PubMed ID: 32772054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive medication strategies for treatment-resistant depression.
    Lam RW
    Can J Psychiatry; 2011 Jun; 56(6):315-6. PubMed ID: 21756444
    [No Abstract]   [Full Text] [Related]  

  • 5. Buprenorphine: prospective novel therapy for depression and PTSD.
    Madison CA; Eitan S
    Psychol Med; 2020 Apr; 50(6):881-893. PubMed ID: 32204739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electroconvulsive therapy is a standard treatment; ketamine is not (yet).
    Kellner CH; Greenberg RM; Ahle GM; Liebman LS
    Am J Psychiatry; 2014 Jul; 171(7):796. PubMed ID: 24980176
    [No Abstract]   [Full Text] [Related]  

  • 7. Ketamine as an alternative treatment for treatment-resistant depression.
    Dowben JS; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
    [No Abstract]   [Full Text] [Related]  

  • 8. Concurrent Use of Buprenorphine, Methadone, or Naltrexone Does Not Inhibit Ketamine's Antidepressant Activity.
    Marton T; Barnes DE; Wallace A; Woolley JD
    Biol Psychiatry; 2019 Jun; 85(12):e75-e76. PubMed ID: 30926131
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of Buprenorphine in treatment of refractory depression-A review of current literature.
    Stanciu CN; Glass OM; Penders TM
    Asian J Psychiatr; 2017 Apr; 26():94-98. PubMed ID: 28483102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy.
    Nyhuis PW; Gastpar M; Scherbaum N
    J Clin Psychopharmacol; 2008 Oct; 28(5):593-5. PubMed ID: 18794671
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression.
    Fawcett J; Rush AJ; Vukelich J; Diaz SH; Dunklee L; Romo P; Yarns BC; Escalona R
    Am J Psychiatry; 2016 Feb; 173(2):107-11. PubMed ID: 26844792
    [No Abstract]   [Full Text] [Related]  

  • 12. Antidepressant augmentation: good news, limitations, and stumbling blocks.
    Kocsis JH
    J Clin Psychiatry; 2015 Apr; 76(4):e526-7. PubMed ID: 25919849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A word to the wise about ketamine.
    Schatzberg AF
    Am J Psychiatry; 2014 Mar; 171(3):262-4. PubMed ID: 24585328
    [No Abstract]   [Full Text] [Related]  

  • 14. The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial.
    Chen SJ; Hsiao YL; Shen TW; Chen ST
    J Clin Psychopharmacol; 2012 Feb; 32(1):56-60. PubMed ID: 22198444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketamine for treatment-resistant depression: ready or not for clinical use?
    Rush AJ
    Am J Psychiatry; 2013 Oct; 170(10):1079-81. PubMed ID: 23982324
    [No Abstract]   [Full Text] [Related]  

  • 16. Potential Pathways Involved in the Rapid Antidepressant Effects of Nitrous Oxide.
    Zarate CA; Machado-Vieira R
    Biol Psychiatry; 2015 Jul; 78(1):2-4. PubMed ID: 26051637
    [No Abstract]   [Full Text] [Related]  

  • 17. Some augmentation strategies improve outcome but increase discontinuation in adults with treatment-resistant depression.
    Andrade C
    Evid Based Ment Health; 2016 May; 19(2):e7. PubMed ID: 27208385
    [No Abstract]   [Full Text] [Related]  

  • 18. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
    Fava M; Okame T; Matsushima Y; Perry P; Weiller E; Baker RA
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):22-30. PubMed ID: 27784751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.
    Fava M; Memisoglu A; Thase ME; Bodkin JA; Trivedi MH; de Somer M; Du Y; Leigh-Pemberton R; DiPetrillo L; Silverman B; Ehrich E
    Am J Psychiatry; 2016 May; 173(5):499-508. PubMed ID: 26869247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
    Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.